This study is NOT currently recruiting participants.
Number
20-C-0098
Sponsoring Institute
National Cancer Institute (NCI)
Recruitment Detail
Type: Completed Study; data analyses ongoing Gender: Male & Female Min Age: 18 Years Max Age: N/A
Referral Letter Required
No
Population Exclusion(s)
Fetuses;Neonates;Pregnant Women;Children
Keywords
Next Cure Inc.; T-cell Activation; Intravenous Infusion; First in Human (FIH); LAIR-2 IgG1 Fusion protein
Recruitment Keyword(s)
None
Condition(s)
Advanced Non-Small Cell Lung Cancer; Metastatic Head and Neck Squamous Cell Carcinoma; Ovarian Cancer; Gastric Cancer; Colorectal Cancer
Investigational Drug(s)
NC410
Investigational Device(s)
Intervention(s)
Drug: NC-410
Supporting Site
National Cancer Institute
Sometimes the body's own immune system may slow down or control cancer growth. Other times, though, this natural immune system response stops, and the cancer is not killed by the immune system. Researchers think a drug called NC410 might be able to help the immune system and people with advanced cancer.
Objective:
To test any good and bad effects of NC410.
Eligibility:
Adults age 18 and older who have advanced cancer or metastatic cancer that has not gotten better after treatment or treatment could not be tolerated.
Design:
Participants will be screened with a medical history. It will include their cancer and medicine history. They will give data on their age, sex, race, and ethnicity. They will have a physical exam. Their height and weight will be measured. Their vital signs, such as blood pressure, temperature, and pulse rate, will be checked. They will be assessed for how their condition impacts their life and activities. They will give blood and urine samples. Their tumors will be measured using imaging scans, such as CT (computed tomography) scans or MRI (magnetic resonance imaging) scans. They will have an electrocardiogram to check heart function.
Some screening tests will be repeated during the study.
Participants will get NC410 every 14 days as an intravenous (IV) infusion. They will get the study drug for up to 12 months, until their cancer gets worse, or until they choose to leave the study.
Participants will have an end-of-treatment visit and 2 safety follow-up visits.
Participation will last for up to 16 months.
--Back to Top--
ELIGIBILITY: Dose escalation (Phase 1a) - Patients with advanced solid tumors who have progressed on standard treatment or have been unable to tolerate standard therapy or who refused standard therapy or for whom no standard therapy exists - Age > 18 years or older
Dose escalation (Phase 1a)
- Patients with advanced solid tumors who have progressed on standard treatment or have been unable to tolerate standard therapy or who refused standard therapy or for whom no
standard therapy exists
- Age > 18 years or older
Principal Investigator
Referral Contact
For more information: